Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 3/20 | 1.00 |
| ▸ | AURKA | O14965 | 2/20 | 1.00 |
| ▸ | CHAT | P28329 | 2/20 | 1.00 |
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 1.00 |
| ▸ | KAT5 | Q92993 | 2/20 | 1.00 |
| ▸ | KAT2B | Q92831 | 1/20 | 1.00 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Coenzyme_A SCHEMBL29402901 | 1.00 | EP300 (1.00) | EP300AURKACHATNAA50KAT5 | |
| Coenzyme_A SCHEMBL26752 | 1.00 | EP300 (1.00) | EP300AURKACHATNAA50KAT5 | |
| Coenzyme_A SCHEMBL18675521 | 1.00 | EP300 (1.00) | EP300AURKACHATNAA50KAT5 | |
| Coenzyme_A SCHEMBL13500623 | 1.00 | EP300 (1.00) | EP300AURKACHATNAA50KAT5 | |
| Coenzyme_A SCHEMBL18682057 | 1.00 | EP300 (1.00) | EP300AURKACHATNAA50KAT5 | |
| Coenzyme_A SCHEMBL18033983 | 1.00 | EP300 (1.00) | EP300AURKACHATNAA50KAT5 | |
| Coenzyme_A SCHEMBL18682056 | 1.00 | EP300 (1.00) | EP300AURKACHATNAA50KAT5 | |
| Coenzyme_A SCHEMBL18180012 | 1.00 | EP300 (1.00) | EP300AURKACHATNAA50KAT5 | |
| Coenzyme_A SCHEMBL26753 | 1.00 | EP300 (1.00) | EP300AURKACHATNAA50KAT5 | |
| Coenzyme_A SCHEMBL18811987 | 1.00 | EP300 (1.00) | EP300AURKACHATNAA50KAT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3595715-B1 | RNA VACCINE AND IMMUNE CHECKPOINT INHIBITORS FOR COMBINED ANTICANCER THERAPY | CureVac SE (DE) | 2026-05-27 | — | — | EP | claimed |
| CN-122046067-A | Power cable grounding fault diagnosis method integrating dynamic wavelet parameters and anti-interference enhancement model | 国网湖北省电力有限公司宜昌供电公司 | 2026-05-15 | — | — | CN | claimed |
| WO-2026099311-A2 | MICROBIAL CELL FACTORIES PRODUCING PROSTAGLANDINS | RIVER STONE BIOTECH APS (DK) | 2026-05-15 | — | — | WO | claimed |
| US-12624272-B2 | Pourable wetting agents and methods associated therewith | SAUDI ARABIAN OIL COMPANY (SA) | 2026-05-12 | — | — | US | claimed |
| EP-3336099-B1 | METHOD FOR SELECTIVELY BINDING CELLS TO A BINDING PARTNER AND DEVICE COMPRISING CELLS | KARLSRUHER INST TECHNOLOGIE (DE) | 2026-03-04 | — | — | EP | claimed |
| EP-4691556-A2 | HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF | H. Lundbeck A/S (DK) | 2026-02-11 | — | — | EP | claimed |
| US-12545899-B2 | Luciferase enzymes for use with thermostable luciferins in bioluminescent assays | PROMEGA CORPORATION (US) | 2026-02-10 | — | — | US | claimed |
| EP-4662192-A1 | MICROORGANISMS AND METHODS FOR REDUCING BY-PRODUCTS | Genomatica, Inc. (US) | 2025-12-17 | — | — | EP | claimed |
| EP-4655403-A1 | GENETIC MODIFICATION OF MICROBES FOR PRODUCTION OF NITROGEN-CONTAINING, NON-CARBON COMPOUNDS | Fertis India Pvt Ltd (IN) | 2025-12-03 | — | — | EP | claimed |
| EP-4655386-A1 | GENETIC MODIFICATION OF MICROBES FOR PRODUCTION OF CARBON-CONTAINING NON-NITROGEN COMPOUNDS | Fertis India Pvt Ltd (IN) | 2025-12-03 | — | — | EP | claimed |
| US-11357723-B2 | Residence structures and related methods | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-06-14 | — | — | US | claimed |
| WO-2022079238-A1 | METHODS OF MODULATING GASTROINTESTINAL METABOLITES | DSM IP ASSETS B.V. (NL) | 2022-04-21 | — | — | WO | claimed |
| EP-3982943-A1 | COMBINATION TREATMENTS FOR CENTRAL NERVOUS SYSTEM DISORDERS | Philera New Zealand Ltd. (NZ) | 2022-04-20 | — | — | EP | claimed |
| CN-216285189-U | A exhaust gas monitoring system for thermal power plant | 华能沁北发电有限责任公司 | 2022-04-12 | — | — | CN | claimed |
| CN-216219124-U | Water-cooled central air conditioner | 珠海格力电器股份有限公司 | 2022-04-08 | — | — | CN | claimed |
| EP-3197436-B1 | COMPOSITIONS AND METHODS FOR SELECTIVE GI TRACT DELIVERY | VITAL BEVERAGES GLOBAL INC (VG) | 2022-03-09 | — | — | EP | claimed |
| EP-3411026-B1 | USE OF STIMULATORS OF SOLUBLE GUANYLATE CYCLASE FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH) | CYCLERION THERAPEUTICS INC (US) | 2022-03-09 | — | — | EP | claimed |
| US-11266730-B2 | Methods of treating and diagnosing disease using biomarkers for BCG therapy | THE GENERAL HOSPITAL CORPORATION (US) | 2022-03-08 | — | — | US | claimed |
| US-11246829-B2 | Residence structures and related methods | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-02-15 | — | — | US | claimed |
| EP-3090043-B1 | 3-HYDROXYISOVALERATE (HIV) SYNTHASE VARIANTS | GLOBAL BIOENERGIES (FR) | 2022-02-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545899-B2 | Luciferase enzymes for use with thermostable luciferins in bioluminescent assays | MAFG, GUSB, MRPL21 | EP300 2585/4885AURKA 3669/4885CHAT 2063/4885 |
| US-11266730-B2 | Methods of treating and diagnosing disease using biomarkers for BCG therapy | LDLR, HMGCR, PCSK9 | EP300 1312/4885AURKA 2328/4885CHAT 1093/4885 |
| US-12624272-B2 | Pourable wetting agents and methods associated therewith | ACIN1, RCC1, AQP3 | EP300 941/4885AURKA 673/4885CHAT 1851/4885 |
| US-11357723-B2 | Residence structures and related methods | SI, VIP, GIPR | EP300 3138/4885AURKA 1357/4885CHAT 2699/4885 |
| US-11246829-B2 | Residence structures and related methods | SI, VIP, GIPR | EP300 3138/4885AURKA 1357/4885CHAT 2699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.